Novavax’s COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study

 Novavax’s COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study

Novavax’s COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study

Shots:

  • The P-III PREVENT-19 study involves assessing the efficacy, safety, and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant vs PBO in 29,960 participants aged ≥18yrs. across 119 sites in the US and Mexico
  • The study demonstrated 100% protection against mod. & sev. disease, 90.4% efficacy overall, and met the 1EPs. The study also showed 93% efficacy against circulating variants of concern and variants of interest & 91% efficacy in high-risk populations
  • The company plans to file for regulatory authorizations in Q3’21, following the completion of the final phases of process qualification and assay validation needed to meet CMC requirements

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post